The situation.
The problem.
The solution.
Our progress.
Key takeaways.
The situation.
EMD-RX7 is a proprietary and unique formulation of ultra pure cannabidiol (CBD) under development with enhanced bioavailability (drug absorption) compared to the current gold standard and EMD-RX5.
EMD-RX7 will seek registration with multiple global regulators as a potential treatment for a range of anxiety disorders and other neurological conditions where Emyria’s proprietary Real-World Evidence (RWE) has shown higher doses of CBD to be safe and effective.
EMD-RX7 is a biopharmaceutical and especially developed to meet all of the purity and safety requirements of major global regulators such as the TGA in Australia and the FDA in the USA.
[The proprietary formulation of EMD-RX7 and associated methods of treatment using the dose form are protected by Emyria’s growing patent portfolio.]
The problem.
The solution.
Our progress.
Key takeaways.